TY - JOUR
T1 - Serum brain-derived neurotrophic factor levels in different neurological diseases
AU - Ventriglia, Mariacarla
AU - Zanardini, Roberta
AU - Bonomini, Cristina
AU - Zanetti, Orazio
AU - Volpe, Daniele
AU - Pasqualetti, Patrizio
AU - Gennarelli, Massimo
AU - Bocchio-Chiavetto, Luisella
PY - 2013
Y1 - 2013
N2 - Consistent evidence indicates the involvement of the brain-derived neurotrophic factor (BDNF) in neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD). In the present study, we compared serum BDNF in 624 subjects: 266 patients affected by AD, 28 by frontotemporal dementia (FTD), 40 by Lewy body dementia (LBD), 91 by vascular dementia (VAD), 30 by PD, and 169 controls. Our results evidenced lower BDNF serum levels in AD, FTD, LBD, and VAD patients (P <0.001) and a higher BDNF concentration in patients affected by PD (P = 0.045). Analyses of effects of pharmacological treatments suggested significantly higher BDNF serum levels in patients taking mood stabilizers/antiepileptics (P = 0.009) and L-DOPA (P <0.001) and significant reductions in patients taking benzodiazepines (P = 0.020). In conclusion, our results support the role of BDNF alterations in neurodegenerative mechanisms common to different forms of neurological disorders and underline the importance of including drug treatment in the analyses to avoid confounding effects.
AB - Consistent evidence indicates the involvement of the brain-derived neurotrophic factor (BDNF) in neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD). In the present study, we compared serum BDNF in 624 subjects: 266 patients affected by AD, 28 by frontotemporal dementia (FTD), 40 by Lewy body dementia (LBD), 91 by vascular dementia (VAD), 30 by PD, and 169 controls. Our results evidenced lower BDNF serum levels in AD, FTD, LBD, and VAD patients (P <0.001) and a higher BDNF concentration in patients affected by PD (P = 0.045). Analyses of effects of pharmacological treatments suggested significantly higher BDNF serum levels in patients taking mood stabilizers/antiepileptics (P = 0.009) and L-DOPA (P <0.001) and significant reductions in patients taking benzodiazepines (P = 0.020). In conclusion, our results support the role of BDNF alterations in neurodegenerative mechanisms common to different forms of neurological disorders and underline the importance of including drug treatment in the analyses to avoid confounding effects.
UR - http://www.scopus.com/inward/record.url?scp=84884277445&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884277445&partnerID=8YFLogxK
U2 - 10.1155/2013/901082
DO - 10.1155/2013/901082
M3 - Article
C2 - 24024214
AN - SCOPUS:84884277445
VL - 2013
JO - BioMed Research International
JF - BioMed Research International
SN - 2314-6133
M1 - 901082
ER -